Fig 1.
Study flow diagram.
Fig 2.
Temporal profile of osteoprotegerin (OPG) during the course of STEMI.
OPG was measured in 255 patients with STEMI at the beginning and immediately after the PCI procedure, at Day 1 (median 14.7 hours after PCI), and at 4-month follow-up. Data are presented as median (boxes) with 25th and 75th percentile (whiskers). *p<0.001 for change in OPG levels from before PCI; **p<0.001 for both change in OPG levels from before PCI and from Day 1. Inset: OPG levels in patients treated with iPost or control.
Table 1.
Clinical and biochemical characteristics of the study population (n = 272).
Table 2.
Associations between osteoprotegerin (OPG) and measurements of myocardial injury and function.
Table 3.
Baseline characteristics of the study population related to osteoprotegerin (OPG) levels measured at Day 1 (above or below median value).
Table 4.
Myocardial injury and function measured by CMR according to osteoprotegerin (OPG) values measured at Day 1.
Table 5.
Univariable and multivariable linear regression analyses of the associations between osteoprotegerin (OPG) measured at Day 1 and final infarct size and left ventricular ejection fraction measured by CMR at 4 months.
Adjusted for clinical and biochemical covariates.
Fig 3.
Osteoprotegerin (OPG) levels in patients with stable coronary artery disease (CAD) before and after heparin administration.
Blood samples were drawn from patients (n = 20) during elective coronary angiography. A venous sample was taken before angiography (A, median 72 min before heparin). Arterial samples were taken immediately after cannulation (B, 1 min before heparin), and at the end of the angiography procedure (C, 20 min after heparin). Data are presented as boxplots, with median (line), 25th and 75th percentile (box) and range (whiskers).